To serotype or not to serotype: That is still the question

Journal of Infectious Diseases

Volumn 195, Issue 5, 2007, Pages 611-614

  Kapikian, Albert Z ^a   Hoshino, Yasutaka ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE NEBRASKA CALF DIARRHEA VIRUS VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

AGE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; INFECTION RESISTANCE; LONGITUDINAL STUDY; NEWBORN INFECTION; NEWBORN PERIOD; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; ROTAVIRUS; SEROTYPE; SEROTYPING; SINGLE DRUG DOSE; VACCINATION; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; HUMANS; INFANT; INFANT, NEWBORN; MICE; ROTAVIRUS; ROTAVIRUS INFECTIONS; SEROTYPING; SWINE;

EID: 33847029973     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510862     Document Type: Editorial

References (51)

1. Banerjee I, Gladstone BP, Le Fevre AM, et al. Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis 2007; 195:625-32 (in this issue).
2. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309:72-6.
3. Greenberg HB, Wyatt RG, Kapikian AZ, Kalica AR, Flores J, Jones R. Rescue and serotypic characterization of noncultivable human rotavirus by gene reassortment. Infect Immun 1982; 37:104-9.
4. Wyatt RG, Greenberg HB, James WD, et al. Definition of human rotavirus serotypes by plaque reduction assay. Infect Immun 1982; 37:110-5.
5. Barnes GI, Lund JS, Adams L, et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Paediatr Child Health 1997; 33:300-4.
6. Barnes GL, Lund JS, Mitchell SV, et al. Early phase II trial of human rotavirus candidate RV3. Vaccine 2002; 20:2950-6.
7. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282-7.
8. Vethanayagam RR, Babu A, Nagalaxmi KS, et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain I321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. J Infect Dis 2004; 189:2282-9.
9. Mata L, Simhon A, Urrutia JJ, Kronmal RA, Fernandez R, Garcia B. Epidemiology of rotaviruses in a cohort of 45 Guatemalan Mayan Indian children observed from birth to the age of three years. J Infect Dis 1983; 148:452-561.
10. Georges-Courbot MC, Monges J, Beraud-Cassel AM, Gouandjika I, Georges AJ. Prospective longitudinal study of rotavirus infections in children from birth to two years of age in Central Africa. Ann Inst Pasteur Virol 1988; 139:421-8.
11. Reves RR, Hossain MM, Midthun K, et al. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children: calculation of risk for second episodes using age-specific person-years of observation. Am J Epidemiol 1989; 130:981-8.
12. Fischer TK, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002; 186:593-7.
13. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8.
14. Velazquez FR, Matson DO, Lourdes Guerrero M, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9.
15. Chiba S, Yokoyama T, Nakata S, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 2:417-21.
16. Vesikari T, Ruuska T, Delem A, Andre F. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr Infect Dis J 1987; 6:164-9.
17. Vesikari T, Karvonen A, Forrrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006; 25:118-22.
18. Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273:1191-6.
19. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the National Multicenter Trial. US Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7-13.
20. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-8.
21. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortent rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 2006; 24:4821-9.
22. Ruiz-Palacios GM, Perez-Schael I, Velazquez F, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
23. Bernstein DI, Sander DS, Smith VE, et al. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991; 164:277-83.
24. Ward RL, Bernstein DI, for lhe US Rotavirus Vaccine Efficacy Group. Protection against rotavirus disease after natural rotavirus infection. J Infect Dis 1994; 169:900-4.
25. Moulton LH, Staat MA, Santosham M, Ward RL. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis 1998; 178:1562-6.
26. Offit PA, Clark HF, Blavat G, Greenberg HB. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. J Virol 1986; 60:491-6.
27. Hoshino Y, Saif LJ, Sereno MM, Chanock RM, Kapikian AZ. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol 1988; 62:744-8.
28. Ward RL, McNeal MM, Sheridan JF. Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. Virology 1992; 188:57-66.
29. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996; 174(Suppl 1):S65-72.
30. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med 2006; 354:23-33.
31. Vesikari T, Karvonen AV, Majuri J, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006; 194:370-6.
32. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-32.
33. Glass RI, Bhan MK, Ray P, et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005; 192:S30-5.
34. Bhandari N, Sharma P, Glass RI, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomized controlled trial. Vaccine 2006; 24:5817-23.
35. Vesikari T, Joensuu J. Review of rotavirus trials in Finland. J Infect Dis 1996; 174(Suppl 1):S81-7.
36. Kapikian AZ, Midthun K, Hoshino Y, et al. Rhesus rotavirus: a candidate vaccine for prevention of human rotavirus disease. In: Lerner RA, Chanock RM, Brown F, eds. Vaccines 85. Molecular and chemical basis of resistance to parasite, bacterial, and viral diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1985:357-67.
37. Flores J, Perez-Schael I, Blanco M, et al. Comparison of the reactogenicity and antigenicity of the M37 rotavirus vaccine and the rhesus rotavirus-based quadrivalent vaccine. Lancet 1990; 336:330-4.
38. Levine MM. Enteric infections and the vaccines to counter them: future directions. Vaccine 2006; 24:3865-73.
39. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele D. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192(Suppl 1):S160-6.
40. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005; 192(Suppl 1):S17-21.
41. Kapikian AZ, Simonsen L, Vesikari T, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries with the potential to eliminate the risk of intussusception. J Infect Dis 2005; 192(Suppl 1):S22-9.
42. Brussow H, Sidoti J, Dirren H, Freire WB. Effect of malnutrition in Equadorian children on titers of serum antibodies to various microbial antigens. Clin Diagn Lab Immunol 1995; 2:62-8.
43. Champsaur H, Questiaux E, Prevot J, et al. Rotavirus carriage, asymptomatic infections, and disease in the first two years of life. I. Virus shedding. J Infect Dis 1984; 149:667-74.
44. Champsaur H, Henry-Amar M, Coldszmidt D, et al. Rotavirus carriage, asymptomatic infection, and disease in the first two years of life. II. Serological response. J Infect Dis 1984; 149:675-82.
45. Nguyen TV, Yuan L, Azevedo MSP, et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol 2006; 13:475-85.
46. Green KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 1990; 161:667-79.
47. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease. Clin Infect Dis 2002; 34:1351-61.
48. Brüssow H, Sidoti J, Barclay D, Sotek J, Dirren H, Freire WB. Prevalence and serotype specificity of rotavirus antibodies in different age groups of Equadorian infants. J Infect Dis 1990; 162:615-20.
49. Conner ME, Crawford SE, Barone C, Estes MK. Serologic and mucosal immune response to rotavirus infection in the rabbit model. J Virol 1991; 65:2562-71.
50. Snodgrass DR, Fitzgerald TA, Campbell I, et al. Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals. J Clin Microbiol 1991; 29:2668-72.
51. Woode GN, Zheng S, Melendy DR, Ramig RF. Studies on rotavirus homologous and heterologous active immunity in infant mice. Viral Immunol 1989; 2:127-32.